The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with Imatinib mesylate predicts for prolonged response at 6 years

Blood Cells, Molecules, and Diseases

Volumn 37, Issue 2, 2006, Pages 111-115

  Piazza, Rocco G ^a   Magistroni, Vera ^a,b   Franceschino, Anna ^a   Andreoni, Federica ^b   Tornaghi, Lucia ^a   Colnaghi, Federica ^a   Corneo, Gianmarco ^a   Pogliani, Enrico M ^a   Gambacorti Passerini, Carlo ^a,c  

^a SAN GERARDO HOSPITAL   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

BCR ABL; Chronic myeloid leukemia; Drug resistance; Imatinib; Remission

Indexed keywords

BCR ABL PROTEIN; IMATINIB;

ADULT; AGED; ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; FOLLOW UP; HUMAN; PREDICTION; PRIORITY JOURNAL; RECURRENCE RISK; REMISSION; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGED; COHORT STUDIES; CYTOGENETIC ANALYSIS; DATA INTERPRETATION, STATISTICAL; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, CHRONIC; MIDDLE AGED; PIPERAZINES; PREDICTIVE VALUE OF TESTS; PYRIMIDINES; RECURRENCE; REMISSION INDUCTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL RATE; TIME; TREATMENT OUTCOME;

EID: 33748788236     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcmd.2006.06.002     Document Type: Article

References (15)

1. O'Brien S.G., Guilhot F., Larson R.A., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 348 (2003) 994-1004
2. Kantarjian H.M., Cortes J.E., O'Brien S., et al. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha. Blood 104 (2004) 1979-1988
3. Guilhot F. Sustained durability of responses plus high rates of cytogenetic responses result in long-term benefit for newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP) treated with imatinib (IM) therapy: update from the IRIS study. ASH, Annu. Meet. Abstr. 104 (2004) 21
4. Hughes T.P., Kaeda J., Branford S., et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 349 (2003) 1423-1432
5. Wu C.J., Neuberg D., Chillemi A., et al. Quantitative monitoring of BCR/ABL transcript during STI-571 therapy. Leuk. Lymphoma 43 (2002) 2281-2289
6. Kantarjian H.M., Talpaz M., Cortes J., et al. Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia. Clin. Cancer Res. 9 (2003) 160-166
7. Piazza R.G., Magistroni V., Andreoni F., et al. Imatinib dose increase up to 1200 mg daily can induce new durable complete cytogenetic remissions in relapsed Ph+ chronic myeloid leukemia patients. Leukemia 25 (2005) 25
8. Piazza R.G., Magistroni V., Gasser M., et al. Evidence for D276G and L364I Bcr-Abl mutations in Ph+ leukaemic cells obtained from patients resistant to Imatinib. Leukemia 19 (2005) 132-134
9. Gabert J., Beillard E., and van der Velden V.H. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia-A Europe Against Cancer program. Leukemia 17 (2003) 2318-2357
10. Gambacorti-Passerini C., Piazza R., Tornaghi L., et al. Development of c-Kit-expressing small-cell lung cancer in a chronic myeloid leukemia patient during imatinib treatment. J. Natl. Cancer Inst. 96 (2004) 1723-1724
11. Iacobucci I., Rosti G., Amabile M., et al. Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. J. Clin. Oncol. 24 (2006) 454-459
12. Zonder J.A., Pemberton P., Brandt H., et al. The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment. Clin. Cancer Res. 9 (2003) 2092-2097
13. Le Coutre P., Kreuzer K.A., Na I.K., et al. Imatinib in Philadelphia chromosome-positive chronic phase CML patients: molecular and cytogenetic response rates and prediction of clinical outcome. Am. J. Hematol. 73 (2003) 249-255
14. Branford S., Rudzki Z., Harper A., et al. Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia 17 (2003) 2401-2409
15. Lahaye T., Riehm B., Berger U., et al. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Cancer 103 (2005) 1659-1669